ArticleEpigenomics2025
SUV39H2 is a vulnerability in glioblastoma stem cells enhanced by co-targeting SUV39H1.
Article in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the role of SUV39H2 in glioblastoma (GBM) stem cells (GSCs) and assess whether co-targeting SUV39H2 and SUV39H1 more effectively disrupts GSC maintenance, offering a potential strategy to improve GBM treatment.
methodsSingle-cell RNA-seq was used to assess SUV39H2 expression in GSCs. GSC growth and stemness were evaluated using tumorsphere formation assay and extreme limiting dilution assay. Gene expression at the mRNA and protein levels was measured by RT-qPCR and western blot, respectively. Publicly available datasets were analyzed to investigate SUV39H2 expression patterns and its clinical prognostic significance in GBM and glioma.
resultsSUV39H2 is overexpressed in GSCs relative to non-stem GBM cells. Its depletion impairs GSC proliferation and stemness. Co-targeting SUV39H2 and SUV39H1 enhances GSC disruption. High SUV39H2 expression correlates with poor glioma prognosis.
conclusionSUV39H2 is a novel regulator of GSC maintenance. Dual targeting of SUV39H2 and SUV39H1 May offer a potential therapeutic approach for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.